On February 3, Roche Products, Ltd. sent a letter to investigators involved in saquinavir studies to alert them that saquinavir/ritonavir should not be coadministered with rifampin due to a risk ...

After AKI develops, more physicians decide to discontinue pyrazinamide, rather than rifampin, implying that they do not know which of the first-line anti-TB drugs is the most common offending drug ...